Mark J Levin
CIK 1180428 · last filed 2021-11-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GBT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. (JNCE) Delisted | 10%+ Owner | 1,432,630 | $1.88 | $2.69M | -$197.76M | 2 | 2021-11-16 |
| FULC | Director | 84,223 | $3.65 | $307.4K | $1.30M | 5 | 2021-11-12 |
| RVMD | 10%+ Owner | 116,334 | $177.96 | $20.70M | -$349.03M | 3 | 2021-06-07 |
| VYGR | Director | 6,424,205 | $1.90 | $12.21M | $0 | 11 | 2021-06-04 |
| NRIX | 10%+ Owner | 3,500,667 | $24.42 | $85.49M | $0 | 1 | 2021-05-10 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 3,034,083 | $33.99 | $103.13M | $0 | 1 | 2018-08-24 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 280,057 | — | — | $0 | 2 | 2018-03-07 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 4,475,191 | $68.49 | $306.51M | -$470.21M | 4 | 2017-04-06 |
| CTMX | 10%+ Owner | 5,170,348 | $2.28 | $11.79M | -$172.20M | 2 | 2017-03-27 |
| Blueprint Medicines Corp (BPMC) Delisted | 10%+ Owner | 3,570,197 | $129.46 | $462.20M | -$1.23M | 1 | 2017-03-20 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 0 | $8.68 | $0 | $0 | 1 | 2015-01-28 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 1 | 2014-03-24 |
| Foundation Medicine, Inc. (FMI) Delisted | Director | 6,569,645 | — | — | $0 | 1 | 2013-10-02 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Director | 400,000 | — | — | -$4.69M | 54 | 2008-05-15 |
Recent Filings · Page 3 of 9
89 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-04-14 | VYGR | Other (J) | −920,000 | $0 | EDGAR |
| 2017-04-06 | Global Blood Therapeutics, Inc. (GBT) Delisted | Other (J) | −12,000,000 | $0 | EDGAR |
| 2017-03-27 | CTMX | Sell (S) | −9,900,000 | -$172.20M | EDGAR |
| 2017-03-20 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −30,000 | -$1.23M | EDGAR |
| 2017-03-06 | Global Blood Therapeutics, Inc. (GBT) Delisted | Sell (S) | −18,407,646 | -$470.21M | EDGAR |
| 2016-12-21 | VYGR | Other (J) | −750,000 | $0 | EDGAR |
| 2016-11-09 | CTMX | Other (J) | −6,000,000 | $0 | EDGAR |
| 2016-11-07 | Global Blood Therapeutics, Inc. (GBT) Delisted | Other (J) | −12,000,000 | $0 | EDGAR |
| 2016-06-17 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2015-11-18 | VYGR | Conv (C) | +10,588,235 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.